Please login to the form below

insulin glargine

This page shows the latest insulin glargine news and features for those working in and with pharma, biotech and healthcare.

FDA adcomm split on Sanofi’s type 1 diabetes drug

The panel voted eight to eight when asked if the overall benefits of Zynquista (sotagliflozin) outweighed its risks as an add-on to insulin treatment for adult patients with type 1 ... It is also a key element in Sanofi’s plans to rebuild its diabetes

Latest news

As France protests, Sanofi takes axe to 670 jobs

The cost-cutting comes as Sanofi is trying to weather the effects of losing patent protection for diabetes blockbuster Lantus (insulin glargine) and build momentum behind new drugs such as atopic
Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity

Xultophy (insulin degludec and liraglutide) which rocketed more than 150% in the first six months of the year to 720m krone. ... 80bn krone on price reductions, competition from generic long-acting insulins including insulin glargine, and cannibalisation
Dupixent bounce-back helps stem diabetes declines at Sanofi

Overall sales at the French pharma group fell almost 6% to 8.3bn ($bn), pegged back by unfavourable exchange rates but also a further 21% drop for Lantus (insulin glargine) due
Sanofi poaches Peugeot's finance head

The group saw sales from its diabetes blockbuster Lantus (insulin glargine) plummet 18% to 911m (1.1bn) in the first quarter, quite a difference from the drug’s peak in 2014,
FDA starts review of Sanofi’s oral type 1 diabetes drug

Sotagliflozin – which has the proposed trade name Zynquista – has been developed as an add-on therapy to insulin injections to help improve blood sugar control in type 1, early-onset diabetes, ... for big-selling basal insulin Lantus (insulin glargine

More from news
Approximately 22 fully matching, plus 116 partially matching documents found.

Latest Intelligence

Deal Watch October 2018

agreement for the development and commercialisation of a follow‐on insulin glargine product to Sanofi’s Lantus.
Mylan sees the UK paving the way for an insulin game changer

As biosimilars surge into the insulin market, governments are urged to seize ‘the opportunity of the century’. ... Mylan, the global healthcare company, has chosen the UK for the launch pad of its much-anticipated biosimilar version of the Sanofi
Going the distance

In fact, its last really big launch was some 14 years ago in the shape of Lantus (insulin glargine), the diabetes blockbuster that is now Sanofi's biggest-selling product. ... Following hot on the heels of Afrezza has been Toujeo (insulin glargine), the
Pharma deals during February 2013

Biosimilars continue to attract. Mylan's third Indian deal is in biosimilars, as it sets up an exclusive strategic collaboration with Biocon for three insulin biosimilars: Biocon's Glargine (the generic ... This deal together with the recent option

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

Sanofi promotes diabetes expert Paul Chew to chief medical officer

position. During his time at Sanofi, Dr Chew has been heavily involved in its growing diabetes business, holding responsibility for its long-acting insulin brand Lantus (insulin glargine), and his appointment

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Medical Writer: Salary TBC

Senior Medical Writer: Up to £50, 000 with Benefits

Account/ Project Director – Medical Affairs – Surrey: Salary TBC

Senior Planner – Healthcare Advertising – New Role: Salary TBC

Project Manager/ Account Manager: Salary TBC

PR Director – Health & Wellbeing – Mat Cover (4 days a week)...: Salary TBC

Project/ Events Manager – Medical Education and Events Agency: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Digital Account Director: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

AD – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Senior Medical Writer: Great salary and benefits

Account Director, Medical Education: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

The importance of co-creation with patients: Overcoming the barriers...
Three billboards on the road to multichannel: Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence: Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....